Intravenous injections of varying doses of 5-HTP (1, 3 and 5mg/100g body wt), a precursor of serotonin, caused a significant and dose-related increase in plasma prolactin concentrations in urethane-anesthetized rats. Increases in plasma prolactin concentrations caused by 5-HTP (1mg/100g body wt iv) were abolished by the concomitant administration of L-DOPA (2mg/100g body wt iv). Plasma prolactin levels were also significantly elevated following the injection of 5-HTP in rats with complete hypothalamic deafferentation, whereas 5-HTP had no significant effect on plasma prolactin levels in rats with extensive hypothalamic ablation.
Prolactin secretion from the pituitary is regulated predominantly by tonic inhibition, possibly via hypothalamic prolactin-inhibiting factor (PIF) (Meites et al., 1972) . It has also been reported that extracts of the hypothalamus stimulate prolactin release (Dular et al., 1974; Valverde et al, 1972) , suggesting the presence of prolactinreleasing factor (PRF) in the hypothalamus. The hypothalamus also contains serotonin in high concentration as well as other biogenic amines (Dahlstrom and Fuxe, 1964) .
Recently, it was demonstrated that the systemic administration of L-tryptophan, a precursor of 5-hydroxytryptophan (5-HTP), or 5-HTP, a precursor of serotonin, raised plasma prolactin levels both in rats (Lu and Meites, 1973) and in man (Kato et al., 1974c; Maclndoe and Turkington, 1973) . The intraventricular injection of serotonin also stimulates prolactin release (Kamberi et al., 1971a) . These results suggest that a serotoninergic mechanism is involved in prolactin secretion, although the exact. mechanism responsible for serotonin-induced prolactin release remains to be clarified.
In the present study, we investigated the effect of 5-HTP on plasma prolactin concentrations in rats with the hypothalamus deafferentated or ablated, in order to elucidate the site of action of the serotoninergic mechanism in regulating prolactin secretion. Radioimmunoassay of plasma prolactin Plasma prolactin concentrations were determined in duplicate by specific radioimmunoassay with the kit supplied by the Rat Pituitary Hormone Program, NIAMDD, as described previously (Kato et al, 1974a) . NIAMDD Rat Prol-I-1 was iodinated with 125I by either the chloramine-T method (Greenwood et al., 1963) or the lactoperoxidase method (Thorell and Johanson, 1971) . NIAMDD Rat Prolactin-RP-1 was used as the standard. The minimum detectable concentration of plasma prolactin was 1ng/ml. The coefficient of variation between assays averaged 9.5%. Statistical analysis was performed by either Student's t test or Duncan's multiple range test (Duncan, 1957 
Results
Effect of 5-HTP on plasma prolactin The intravenous injection of varying doses of 5-HTP (1, 3 and 5mg/100g body wt) caused a significant increase in plasma prolactin levels as shown in Fig. 1 . Peak levels of plasma prolactin were observed 20 to 40min after 5-HTP administration. The mean (+S. E. M.) peak value of plasma prolactin after 1mg of 5-HTP per 100g body wt was 25.7+7.8ng/ml, which was significantly higher than the saline control (P< 0.01). The mean peak value of plasma prolactin in rats given 3mg of 5-HTP per 100g body wt was higher than that in rats (Fig.2) . A single intravenous injection of the vehicle (pH 2.8) had no significant effect on plasma prolactin levels although the data are not shown.
Plasma prolactin responses to 5-HTP in rats with hypothalamic deafferentation
The basal plasma prolactin levels were 16.1+3.1 ng/ml (mean + S. E. M.) in rats with complete hypothalamic deafferentation. Plasma prolactin levels rose significantly following the administration of 5-HTP (1mg/100g body wt iv) as shown in Fig.  3 Lu et al. (1973) reported that a large dose of 5-HTP (12.5mg/100g body wt) given intravenously raised serum prolactin levels in female rats. It was also reported that the intraperitoneal injection of 5-HTP (30mg/rat) raised serum prolactin levels in ovariectomized estrogen primed rats (Chen and Meites, 1975) . However, Smythe and Lazarus (1973) described that a smaller dose of 5-HTP (0.8mg/100g body wt ip) caused a slight but non-significant rise in plasma prolactin levels in male rats. We have demonstrated in this study that a single intravenous injection of 5-HTP (1, 3 and 5mg/100g body wt) caused a marked and dose-related increase in plasma prolactin concentrations in urethane-anesthetized male rats. Kamberi et al. (1971a) reported that the injection of serotonin into the third ventricle increased prolactin levels in the blood, and suggested the possible role of a serotoninergic mechanism in stimulating prolactin release.
We have previously shown that the oral administration of 5-HTP raised plasma prolactin in man and concomitant intravenous infusion of cyproheptadine, a serotonin antagonist, significantly blunted the plasma prolactin response to 5-HTP (Kato et al., 1974c ). An increase of brain serotonin can be expected following the systemic administration of 5-HTP, a precursor of serotonin known to enter the brain (McBride et al., 1974) . It can be assumed, therefore, that 5-HTP causes prolactin release by stimulating the serotoninergic mechanism.
However, the exact site of action of serotonin in stimulating prolactin release remains to be clariWe then studied the effect of 5-HTP on plasma prolatin levels in rats with hypothalamic deafferentation or extensive hypothalamic destruction.
The intravenous injection of 5-HTP caused a marked rise in plasma prolactin levels in rats with complete hypothalamic deafferentation. However, no significant change in plasma prolactin was observed in rats with hypothalamic ablation.
It is known that interruption of the portal vasculature results in extensive necrocsis of the pituitary (Daniel and Prichard, 1965; David et al., 1965) . However, the anterior pituitaries were kept intact except occasional small central infarct following hypothalamic destruction in the present experiment. These findings were in agreement with other reports (Arimura et al., 1972; Dunn and Critchlow 1973) , in which similar hypothalamic surgery was performed. The ability of chlorpromazine to increase prolactin release in rats with hypothalamic ablation also indicates that this animal preparation can release prolactin in response to stimuli, despite the elevated control levels. The inability of 5-HTP to increase prolactin release is, therefore, not due to the damage of the pituitary caused by the surgery.
These results suggest that 5-HTP does not act directly on the pituitary gland but exerts its prolactin-releasing activity at the level of the hypothalamus. Talwalker et al. (1963) also reported that the direct action of serotonin in stimulating prolactin release from the pituitary gland was ruled out by an in vitro experiment. It appears, therefore, that 5-HTP causes prolactin release by stimulating the serotoninergic mechanism in the hypothalamus.
Basal plasma prolactin levels were much higher in rats with hypothalamic ablation than in intact rats as well as in rats with complete hypothalamic deafferentation. These results are in agreement with those reported by Krulich et al. (1975) , suggesting a tonic inhibitory regulation by the isolated hypothalamic islands. We have found that 5-HTP (1mg/100g body wt iv) administration caused a much higher increase in prolactin release in rats with complete hypothalamic deafferentation than in intact animals. Serotonin imput to the hypothalamus originating in the raphe nuclei in the midbrain (Fuxe and Hokfelt, 1964) is interrupted by complete hypothalamic deafferentation and the isolated hypothalamus may become hypersensitive to serotonin, which may potentiate plasma prolactin response to 5-HTP in rats with complete hypothalamic deafferentation.
We have also demonstrated that plasma prolactin responses to 5-HTP were significantly suppressed by L-DOPA, a precursor of dopamine. Evidence has been reported suggesting that dopamine is related to prolactin-inhibiting factor (PIF) (Kamberi et al., 1971b; VanMaanen and Smelik, 1968) and that prolactin release is regulated by a dual, serotoninergic and dopaminergic, mechanism (Kamberi et al., 1971a) . Our results suggest that there exist some interactions between serotoninergic and dopaminergic mechanisms, although the exact nature of the interactions is not clear. Some recent studies (MacLeod and Lehmeyer, 1974; Takahara et al., 1974) have provided evidence suggesting a direct inhibitory action of dopamine on pituitary prolactin release. Our observation that chlorpromazine produced a significant increase in plasma prolactin levels in rats with extensive hypothalamic destruction also indicates a possible direct action of the drug on the pituitary.
Since chlorpromazine is wellknown as a dopamine antagonist, it might stimulate prolactin release by antagonizing the inhibitory action of dopamine at the pituitary level, although other actions of the drug (Anden et al., 1967 ) cannot be ruled out.
